Pathology: Decoding Your Pituitary Tumor (PitNET) Report
At a Glance
A pituitary pathology report for Cushing disease identifies the tumor's specific characteristics, now officially called a PitNET. Key markers like T-PIT confirm the tumor's origin, while the Ki-67 index and USP8 mutation status help doctors predict tumor behavior and plan future treatments.
When your neurosurgeon removes the tumor causing your Cushing disease, the tissue is sent to a laboratory where a pathologist examines it under a microscope. This examination results in a Pathology Report, which is the final word on what was growing in your pituitary gland.
The New Name: PitNET
You may notice a change in how your tumor is described. In 2022, the World Health Organization (WHO) updated the official name for pituitary tumors from “Pituitary Adenoma” to Pituitary Neuroendocrine Tumor, or PitNET [1][2].
- Why the change? The term “adenoma” implies a simple, harmless growth. Doctors moved to “PitNET” to recognize that these tumors are biologically active and can vary in how they behave—some are very quiet, while others are more persistent [3].
- Is it cancer? For the vast majority of patients, the answer is no. While “tumor” is a scary word, the “PitNET” label is used to help doctors better predict how the tumor might grow or respond to treatment, rather than to label it as a malignancy [4][1].
Key Markers to Look For
A modern pathology report uses immunohistochemistry (staining the cells with special dyes) to identify the specific “fingerprint” of your tumor [5].
1. T-PIT: The Lineage Marker
This is the most important “identity” marker for Cushing-related tumors. T-PIT is a transcription factor—a protein that acts like a master switch to turn a cell into a “corticotroph” (an ACTH-producing cell) [6]. If your tumor is T-PIT positive, it confirms the tumor belongs to the family of cells that causes Cushing disease [7].
2. ACTH Staining
This confirms the tumor was actively producing Adrenocorticotropic Hormone (ACTH) [8]. In some cases, a tumor may be “silent,” meaning it is T-PIT positive but not actually pumping ACTH into your blood [9].
3. Crooke’s Hyaline Change
You might see this unusual phrase on your report. Crooke’s hyaline change is a glass-like appearance that happens to normal pituitary cells when they are exposed to very high levels of cortisol [10].
- What it means: Finding this change in the normal tissue next to the tumor is actually a good sign—it proves that your body was indeed under “cortisol stress” and that the surgeon likely found the right spot [11].
Molecular Insights: The USP8 Mutation
Recent research has discovered that about half of all ACTH-secreting tumors have a specific genetic mutation called USP8 [12].
- The “Good” Mutation: If your tumor has a USP8 mutation, it is often associated with smaller, less invasive tumors and a higher chance of achieving full remission after surgery [13][14].
- Treatment Clues: Tumors with this mutation may also respond better to specific medications, such as pasireotide, if the disease ever returns [15].
Your Completeness Checklist
When you review your report with your doctor, ensure these four elements are present to have a complete picture of your diagnosis [5][16]:
- Lineage Confirmation: Does it mention T-PIT or Corticotroph lineage?
- Proliferation Index: Does it list a Ki-67 percentage? (Lower than 3% is usually considered less aggressive) [17].
- Invasion Status: Does the pathologist mention if the tumor was growing into nearby structures like the cavernous sinus?
- Hormone Profile: Does it confirm ACTH positivity?
By understanding these markers, you and your medical team can move from “guessing” how your body will recover to having a data-driven plan for your long-term health.
Common questions in this guide
Why is my pituitary tumor now called a PitNET instead of an adenoma?
What does T-PIT positive mean on my pathology report?
What is Crooke's hyaline change?
What does a USP8 mutation mean for my pituitary tumor?
Why is the Ki-67 index important on my pathology report?
Related questions
Get notified when new evidence is published on Cushing disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal.
Asa SL, Casar-Borota O, Chanson P, et al.
Endocrine-related cancer 2017; (24(4)):C5-C8 doi:10.1530/ERC-17-0004.
PMID: 28264912 - 2
Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL, Mete O, Perry A, Osamura RY
Endocrine pathology 2022; (33(1)):6-26 doi:10.1007/s12022-022-09703-7.
PMID: 35291028 - 3
A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
Woo CS, Ho RS, Ho G, et al.
Frontiers in endocrinology 2024; (15()):1368944 doi:10.3389/fendo.2024.1368944.
PMID: 38756997 - 4
Pituitary Neuroendocrine Tumor: Is It Benign or Malignant?
Lee CH
Brain tumor research and treatment 2023; (11(3)):173-176 doi:10.14791/btrt.2023.0015.
PMID: 37550816 - 5
Pituitary adenomas: biology, nomenclature and clinical classification.
Ho KKY, Melmed S
Reviews in endocrine & metabolic disorders 2025; (26(2)):137-146 doi:10.1007/s11154-025-09944-x.
PMID: 39862335 - 6
Overexpression of T-box Transcription Factor 5 (TBX5) Inhibits Proliferation and Invasion in Non-Small Cell Lung Carcinoma Cells.
Ma R, Yang Y, Tu Q, Hu K
Oncology research 2017; (25(9)):1495-1504 doi:10.3727/096504017X14883287513729.
PMID: 28276311 - 7
Transcription factor-based classification of pituitary adenomas / PitNETs: a comparative analysis and clinical implications across WHO 2004, 2017 and 2022 in 921 cases.
Nasi-Kordhishti I, Hladik M, Kandilaris K, et al.
Acta neuropathologica communications 2025; (13(1)):135 doi:10.1186/s40478-025-02050-8.
PMID: 40579705 - 8
Liver metastases from pituitary carcinomas mimicking visceral well-differentiated neuroendocrine tumors: a series of four cases.
Venable ER, Kerr SE, Lopes MBS, et al.
Diagnostic pathology 2020; (15(1)):81 doi:10.1186/s13000-020-00997-x.
PMID: 32622369 - 9
Delineating the Spectrum of Pituitary Adenoma Based on the WHO 2017 Classification.
Paramita P, Shilpa R, Nandeesh BN, et al.
Neurology India 2024; (72(1)):96-101 doi:10.4103/neuroindia.NI_913_20.
PMID: 38443009 - 10
USP8, USP48, and BRAF mutations differ in their genotype-phenotype correlation in Asian Indian patients with Cushing's disease.
Abraham AP, Pai R, Beno DL, et al.
Endocrine 2022; (75(2)):549-559 doi:10.1007/s12020-021-02903-x.
PMID: 34664215 - 11
Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease.
Akirov A, Larouche V, Shimon I, et al.
Frontiers in endocrinology 2021; (12()):620005 doi:10.3389/fendo.2021.620005.
PMID: 33815279 - 12
PATHOGENESIS OF CUSHING DISEASE: AN UPDATE ON THE GENETICS OF CORTICOTROPINOMAS.
Albani A, Perez-Rivas LG, Reincke M, Theodoropoulou M
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2018; (24(10)):907-914 doi:10.4158/EP-2018-0111.
PMID: 30084690 - 13
Relevance of mutations in protein deubiquitinases genes and TP53 in corticotroph pituitary tumors.
Pękul M, Szczepaniak M, Kober P, et al.
Frontiers in endocrinology 2024; (15()):1302667 doi:10.3389/fendo.2024.1302667.
PMID: 38487343 - 14
USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors.
Uzilov AV, Taik P, Cheesman KC, et al.
The Journal of clinical endocrinology and metabolism 2021; (106(3)):826-842 doi:10.1210/clinem/dgaa853.
PMID: 33221858 - 15
The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.
Hayashi K, Inoshita N, Kawaguchi K, et al.
European journal of endocrinology 2016; (174(2)):213-26 doi:10.1530/EJE-15-0689.
PMID: 26578638 - 16
Clinical and Pathological Features of Pit1/SF1 Multilineage Pituitary Neuroendocrine Tumor.
Wang X, Tang H, Bie Z, et al.
Neurosurgery 2024; doi:10.1227/neu.0000000000002846.
PMID: 38289085 - 17
Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas.
Heng L, Liu X, Jia D, et al.
Clinical endocrinology 2021; (95(1)):134-142 doi:10.1111/cen.14465.
PMID: 33738801
This page explains PitNET and Cushing disease pathology terminology for educational purposes only. Always discuss your specific pathology report results with your neuroendocrinologist or neurosurgeon.